
Drones Deliver Millions Of Mosquitos to Prevent Bird Extinctions In Hawai‘i
'Ākohekohe (Palmeria dolei), or crested honeycreeper, is endemic to the island of Maui in Hawaiʻi. ... More The ʻākohekohe is susceptible to mosquito‐transmitted avian malaria and only breeds in high‐elevation wet forests. It is critically endangered with fewer than 2,000 individuals alive today. (Via USFWS / public domain.)
In a brilliant demonstration of multidisciplinary collaboration, a conservation program to save Hawai'i's critically endangered native bird species has taken another step forward. After a team of scientists developed sterile male mosquitoes, the next challenge was to safely deliver them to where they would be most effective in Hawai'i.
Sterile male mosquitoes are created by infecting them with the bacteria, Wolbachia. This bacteria, which naturally occurs in many wild insect species, interferes with reproduction in mosquitoes by 'sterilizing' the males when introduced into mosquito populations like Aedes aegypti. When sterile male Wolbachia-infected mosquitoes mate with invasive wild female Aedes aegypti mosquitoes, the resulting eggs cannot be fertilized and thus, cannot hatch, thereby reducing the mosquito population.
Wolbachia is a maternally transmitted bacterium, where female Wolbachia-carrying Aedes aegypti pass ... More the bacterium to their offspring, thus generating a stable line of Wolbachia-Aedes mosquitoes. Rearing this line of mosquitos in captivity allows humans to easily produce large numbers of incompatible male Wolbachia-Aedes mosquitoes for release. (Credit: The National Environment Agency of Singapore / Public Domain)
Male mosquitoes (regardless of whether they carry Wolbachia) do not bite or transmit disease, and feed only on plant juices and nectar for survival and energy. On the other hand, female mosquitoes do bite because they need a fresh blood meal to produce eggs. Additionally, because Wolbachia-Aedes mosquitoes are not genetically modified, and because Wolbachia bacteria naturally occur in 60% or more wild insects, these mosquitoes are safe.
Where did these 'sterile' male mosquitoes originate?
'These males are descendants of mosquitoes originally collected from Hawai'i and it has taken multiple mosquito generations to breed up enough IIT mosquitoes to supply the project's needs,' said scientific outreach specialist Emma Shelly, who works as the Outreach Manager with Birds, Not Mosquitoes. This is a multi-agency partnership, spearheaded by the American Bird Conservancy, that is working to protect native Hawaiian honeycreepers from extinction caused by avian diseases, particularly avian malaria, transmitted by invasive mosquitoes.
The effort uses the Incompatible Insect Technique (IIT) as a biological 'birth control' method to reduce the spread of mosquito-borne diseases by reducing local mosquito populations by more than 80% (ref). It has been used successfully in a wide range of places and situations around the world to control a variety of mosquito-borne diseases, ranging from dengue fever to malaria.
Do free-roaming female mosquitoes prefer to mate with these IIT male mosquitoes?
'So all things being equal, matings would occur at random,' Ms Shelly told me in email. 'But all things aren't equal because the project is heavily skewing the odds in favor of the incompatible males by releasing them in such large numbers that the wild male mosquitoes are overwhelmed. In this scenario, wild females have significantly more opportunities to encounter IIT males and mate with them.'
This technique is known as 'overflooding' and the 'overflooding ratio' (how many IIT males it takes to overwhelm wild males in a given area) is a key component of the project. In Hawai'i, that ratio is 10:1.
Not only can drones deliver missiles to protect beleaguered civilians from Russian terrorists, but drones can also deliver pods full of IIT male mosquitoes to protect critically endangered Hawai'ian honeycreepers from avian malaria. But the drones used in these biological battles are not the same as those used against Russia, as you might have guessed.
'The drones we use are more common for activities requiring a moderate payload for a drone, like LiDAR, magnetometers, or cinema cameras. They are usually somewhat larger and fly much slower,' Adam Knox, drone pilot and Aerial Deployment of Mosquitoes Project Manager for American Bird Conservancy, told me in email. 'One of the drones we use, the Freefly AltaX is used for movies (can carry a RED Epic or similar) as well as aerial ignition deployment for controlled wildfire burns.'
What makes these particular drones particularly well-designed to carry out their mosquito-delivery job?
'The drones needed to have adequate range and endurance to reach the 3000 acre site that extends over mountainous terrain carrying the payload system and then return home, so much of the testing has been focused on demonstrating this,' Mr Knox explained in email.
Are these drones guided by autopilot or by humans?
'Both,' Mr Knox replied in email. 'A human pilot flies the aircraft manually during takeoffs and landings to precisely navigate around hazards in the forest, then once above the tree canopy, the aircraft is switched into an autopilot mode which allows it to carry out the preplanned mission as the pilot monitors the flight.'
The male mosquitoes are delivered in biodegradable pods. Each drone carries up to 23 mosquito pods in one flight, and each pod contains about 1,000 insects.
'The pods are made of a sterilized biodegradable paper pulp and are not reusable,' Mr Knox explained in email. 'Once released from the air, they fall to the forest floor where they provide protection to the mosquitoes until they're ready to fly away. The pods then begin to break down once exposed to the elements.'
A drone carrying a biodegradable mosquito pod, loaded and ready to deliver. (Credit: Adam Knox, ... More image appears here courtesy of the American Bird Conservancy.)
This effort is the first known instance of specially-designed mosquito pods being dropped by drones. One of several pod design challenges that had to be met before the drone delivery service could be launched was the pods needed to maintain a controlled temperature. Unlike other insect species that have been released directly from drones in other parts of the world, these male mosquitoes are fragile and require containment in temperature-controlled pods.
'It's extremely exciting to have reached this project milestone,' Mr Knox remarked in email. 'The first drone deployments took place in April 2025. It took a lot of hard work and reliance on strong partnerships to reach the point where we could successfully demonstrate the utility and potential of drone aircraft as a tool for this important work, especially in one of the more challenging environments in the world.'
The mosquito deliveries occur over thousands of acres of remote, mountainous terrain that have significant elevational changes, strong winds, and frequent rain. The drones and their release systems had to be tested in these demanding conditions to validate their ability to carry out the basic components of the mission.
Can you imagine dropping mosquitoes in this landscape without falling to your death? Aerial view of ... More the rugged terrain, steep walls and waterfalls at Koolau Forest Reserve East Maui, Hawaii. (Credit: Forest and Kim Starr / CC BY 3.0 US)
Originally, mosquito deliveries began in 2023 with twice weekly helicopter deployments into remote forests on Maui and Kaua'i, but drone deployments are so much safer for the humans delivering the mosquitoes.
'This opens up a lot of possibilities now and into the future,' Mr Knox pointed out. 'With a drone, we have more flexibility with deployment timing in areas that generally have very unpredictable weather, and it's safer because no humans need to ride in the aircraft as pilot and crew to deploy the mosquitoes.'
Your job looks like it's fun. Is it?
'My parents got me a Tyco Wild Thing as my first RC car when I was probably 5 or 6 years old and since then I have been into the RC hobby on and off throughout my life, spanning cars, planes, helicopters and drones,' Mr Knox replied in email. 'To be able to have my professional pursuits overlap with a hobby that brings me joy is something many only dream about so I feel incredibly lucky to have the opportunity to apply this skillset and knowledge toward helping some of the most endangered wildlife on the planet.'
"What we're doing is difficult and it has required a lot of long days for dozens of people scattered across the country working together over multiple years now,' Mr Knox replied in email. 'It's been worth every ounce of effort with what we've been able to learn while getting these specialized IIT mosquitoes out into some of the most challenging landscapes imaginable in order to give these birds a fighting chance at recovery.'
Even as these IIT mosquitoes are being delivered to their targets, are there other conservation efforts ongoing?
'Yes, there are,' Mr Knox replied in email. 'The San Diego Zoo Wildlife Alliance has two facilities in Hawai'i where small populations of several endangered bird species are being kept and captively bred. The sooner mosquitoes are suppressed, the sooner these critically endangered birds can be returned to the wild and begin to re-establish themselves.'
Whilst the IIT mosquito effort is currently the best tool we have for controlling invasive disease-carrying mosquitoes, it works hand in hand with other conservation efforts being led on the ground by Birds, Not Mosquitoes partners, including habitat restoration and invasive species and predator control.
A critially endangered Hawai'ian Kiwikiu (Pseudonestor xanthophrys) or hookbilled honeycreeper. ... More There are fewer than 200 of these birds remaining. (Credit: Robby Kohley, image appears here courtesy of the American Bird Conservancy.)
The mosquito, Aedes aegypti, was initially introduced to the Hawaiian Islands sometime after 1882 by whaling ships, so any ecological role these insects may fill either as prey or pollinators is a recent development. Which is another way to say that it is extremely unlikely that any native bird species has become dependent upon them as a critical food resource. But this invasive mosquito species is quite efficient at transmitting a variety of debilitating diseases to humans, such as dengue, chikugunya, Zika virus, and malaria, just to name a few.
Originally, the Aedes aegypti mosquito was restricted to Hawai'i's lower elevations, which allowed some of Hawai'i's honeycreepers to live at higher elevations and thus survive. However, climate change has allowed mosquitoes to expand their range upwards, so now all of Hawai'i's remaining native bird species are in danger of vanishing forever.
'Without significantly reducing invasive mosquito populations, multiple native bird species will disappear forever in the near future,' said Chris Farmer, the American Bird Conservancy's Hawai'i Program Director.
How many native Hawai'ian bird species have been driven extinct by avian malaria so far?
'At least 33 species of honeycreeper are now extinct, and many of the 17 that remain, including the Kiwikiu and ʻĀkohekohe on Maui, and ʻAkekeʻe on Kauaʻi, are highly endangered,' Dr Farmer replied. 'Last year, the ʻAkikiki became functionally extinct in the wild, and mosquitoes could cause other species to quickly decline and vanish if no action is taken.'
The ʻakikiki (Oreomystis bairdi), also called the Kauaʻi creeper, is now functionally extinct, ... More thanks to avian malaria spread by invasive mosquitoes. (Credit: Robby Kohley, image appears here courtesy of American Bird Conservancy.)
'Reducing invasive mosquito populations is absolutely critical in preventing the extinction of Hawai'i's vulnerable honeycreepers,' Dr Farmer continued. 'We have the technology to break the avian disease cycle in Hawai'i, and a fighting chance to restore populations. We are the generation that can save honeycreepers like Maui's Kiwikiu, and with a population of less than 150 individuals, these drone and mosquito suppression advancements have come just in time.'
I highly recommend that you watch this moving video, Vanishing Voices, which shows how ABC is working with its Birds, Not Mosquitoes partners to prevent the extinction of the iconic native bird species in Hawai'i. This wonderful, hopeful video shares the gorgeous songs of these vanishing birds.
© Copyright by GrrlScientist | hosted by Forbes | LinkTr.ee
Socials: Bluesky | CounterSocial | LinkedIn | Mastodon Science | MeWe | Spoutible | SubStack | Threads | Tumblr | Twitter
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale
AI heart failure diagnostics innovator makes it possible to catch deadly heart failure earlier by analyzing the most common heart scan in the world and proactively alerting clinicians FDA-cleared, reimbursed by Medicare, and live in top U.S. hospitals, Ultromics is now scaling nationwide to make early heart failure detection part of routine cardiac care, wherever patients get an echo Ultromics is trained on one of the largest real-world echo datasets globally and validated across 25 peer-reviewed studies, helping close one of medicine's most dangerous diagnostic gaps, where up to 64% of heart failure cases still go undetected OXFORD, England, July 31, 2025 /PRNewswire/ -- Ultromics, a pioneer in AI-driven cardiology solutions, today announced it has raised $55 million in Series C financing. The round was co-led by L&G, Allegis Capital and Lightrock, with continued support from Oxford Science Enterprises, GV, Blue Venture Fund and Oxford University. Major U.S. health systems, including UChicago Medicine's venture investment vehicle, UCM Ventures, and UPMC Enterprises also participated in the round. Built on years of clinical study and hundreds of thousands of echo scans, Ultromics offers the first FDA-cleared, Medicare-reimbursed AI technology to help clinicians detect HFpEF and cardiac amyloidosis, two of the most elusive forms of heart failure. The company is now expanding across the U.S. to bring that capability to the hospitals and echo labs that see the highest volume of at-risk patients, aiming to make AI-enhanced diagnostics a default step in the cardiac workup. Ultromics is also expanding its pipeline to include additional cardiac conditions, new distribution channels and deeper partnerships with health systems and clinical leaders. It's a critical moment for cardiovascular care. Heart failure is rising, costs are mounting and millions of patients are still going undiagnosed, especially those with harder-to-detect forms like HFpEF and cardiac amyloidosis. In the U.S. alone, heart failure drives over $30 billion in annual healthcare costs, a number projected to exceed $70 billion by 2030. Clinicians often rely on subjective interpretation of echocardiograms, leading to missed or delayed diagnoses even when patients are actively seeking care. In fact, up to 64% of HFpEF cases go undiagnosed, and cardiac amyloidosis is frequently mistaken for more common forms of heart disease, leaving patients untreated until symptoms worsen or irreversible damage occurs. Ultromics addresses this diagnostic blind spot by using AI to extract hidden disease signals from standard echocardiograms, enabling earlier, more accurate detection of complex heart conditions—without requiring new hardware or disrupting clinical workflows. Its FDA-cleared EchoGo® platform supports diagnosis of HFpEF and cardiac amyloidosis. Trained and validated on one of the largest real-world echo datasets globally, EchoGo® generates real-time probability scores to help cardiologists identify high-risk patients earlier than traditional methods. EchoGo® is fully reimbursed under Medicare, making it scalable across hospitals, clinics, and health systems nationwide. "The reality is, hospitals already have the data, they just haven't had the tools to extract the more subtle diagnostic signals from it. By analyzing routine echocardiograms with AI, we're helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses," said Ross Upton, PhD, CEO and Founder, Ultromics. "We've spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis." Ultromics has already analyzed more than 430,000 echocardiograms to date. In clinical studies, EchoGo® improved the detection of HFpEF by 73.6% when compared with standard clinical risk scores. The company's latest diagnostic model for cardiac amyloidosis, validated in a global study of 18 institutions and published in the European Heart Journal, outperformed current clinical risk scores while distinguishing disease from similar conditions. "Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies," said Alastair Stewart, Head of Investments, Venture Capital, at L&G. "This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year." With growing adoption and partnerships across flagship institutions, including UChicago Medicine, University Hospitals Cleveland, Northwestern, and Mayo Clinic, Ultromics is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions like the Midwest. Its platform is helping hospitals reduce unnecessary tests, streamline workflows and initiate treatment earlier so it's more effective and less expensive. "Heart failure and cardiac amyloidosis impact millions of lives and strain healthcare systems, despite new approaches that have the potential to significantly improve patient outcomes. There is a critical need for scalable solutions that enable earlier, more accurate diagnosis and elevate the standard of care," said Umur Hursever, Partner at Lightrock. "Ultromics' AI-driven technology is already making a real-world impact, improving diagnostic accuracy, supporting clinical decisions, and expanding access to specialist care. The Lightrock team is delighted to support Ultromics' mission and growing impact." Ultromics has rapidly expanded its platform capabilities and U.S. market presence during the past year. In late 2024, the company received FDA Breakthrough Device clearance for EchoGo® Amyloidosis, followed in 2025 by the launch of EchoGo® Score, a new feature that adds AI-driven probability scoring to EchoGo® Heart Failure, helping clinicians detect HFpEF with greater nuance. These clinical advances are now supported by Medicare reimbursement for both outpatient and inpatient use, strengthening Ultromics' foundation for scaled adoption across U.S. hospitals. "There's a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle and echo images are hard to interpret," said Victor Westerlind, Managing Director at Allegis Capital. "What's exciting about Ultromics is how they're closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it's a diagnostic win that will help save lives." About Ultromics Founded out of the University of Oxford, Ultromics is redefining cardiovascular care with FDA-cleared, AI-powered tools that enhance echocardiographic diagnosis. Built in partnership with the NHS and Mayo Clinic, its EchoGo® platform helps clinicians detect complex heart diseases earlier and more accurately—using nothing more than a standard ultrasound scan. Ultromics is backed by leading investors and U.S. healthcare systems and is on a mission to transform how heart disease is diagnosed and treated. For more, visit About Lightrock Lightrock is a global investment platform committed to building a sustainable future. Operating across private and public markets, Lightrock manages over $5.5 billion in assets and invests in Europe, North America, Latin America, Asia, and Africa. Lightrock is a certified B Corp with a dedicated team of over 130 professionals working across a network of six offices For more information, visit About L&G Established in 1836, L&G is one of the UK's leading financial services groups and a major global investor, with £1.1 trillion in total assets under management (as at FY24) of which c. 44% (c. £0.5 trillion) is international. We have a highly synergistic business model, which continues to drive strong returns. We are a leading player in Institutional Retirement, in Retail Savings and Protection, and in Asset Management through both public and private markets. Across the Group, we are committed to responsible investing and dedicated to serving the long-term savings and investment needs of customers and society. About Allegis Capital Allegis Capital is an early-stage venture capital firm partnering with companies that enable digital transformation across the enterprise. The firm supports founders with hands-on guidance, operational expertise, and access to a global network of industry leaders. With a long track record of building market-defining businesses, Allegis backs the teams and platforms reshaping how work gets done. Headquartered in Palo Alto, California, Allegis has been investing in enterprise innovation for over two decades. For more information, visit Photo - - View original content to download multimedia: SOURCE Ultromics Sign in to access your portfolio


Medscape
19 minutes ago
- Medscape
GLP-1 Agonists for Type 2 Diabetes Reduce Psoriasis, HS Risk
TOPLINE: Treatment with glucagon like peptide 1 receptor agonist (GLP-1 RA) medications was associated with a lower risk of being diagnosed with hidradenitis suppurativa (HS) or psoriasis, in a study of patients with type 2 diabetes (T2D). METHODOLOGY: Researchers assessed 74,910 patients (mean age, 65 years; 56% women; 45% White and 23% Black individuals) with T2D from the All of Us Database between May 2018 and October 2023. Of all patients, 19.5% received GLP-1 RAs. The primary outcomes of the study were risks for HS and psoriasis, adjusted for effects on control of diabetes and weight loss. TAKEAWAY: Overall, 1601 patients had psoriasis (mean age, 68 years; 56.4% women; 62.4% White and 12.2% Black individuals), and 601 had HS (mean age, 55 years; 77.2% women; 32.9% White and 41.3% Black individuals). Patients treated with GLP-1 RAs showed a significantly lower risk for a future diagnosis of HS (adjusted odds ratio [OR], 0.61; P < .001) than those who were not treated with GLP-1 RAs. GLP-1 RA treatment was also associated with a significant reduction in the risk for a future diagnosis of psoriasis (adjusted OR, 0.41; P < .001). The average time from T2D diagnosis to a diagnosis of HS was 3.98 years and 3.44 years to a diagnosis of HS. IN PRACTICE: 'These findings support a protective effect against HS and psoriasis in patients with T2DM taking GLP-1 RAs independent of weight loss, smoking status, or glycemic control,' the study authors wrote. Based on these findings, they added, 'future research should focus on prospective studies exploring the use of GLP-1 RAs as therapeutic tools to treat HS or psoriasis, prevent disease progression, and evaluate their effect in patients without diabetes.' SOURCE: The study was led by Lauren M. Ching, Georgetown University School of Medicine, Washington, DC, and was published online on July 23, 2025, in JAAD International. LIMITATIONS: Limitations included variance in data harmonization across sites, lack of disease severity information, and selection bias. DISCLOSURES: The study did not receive any funding. One author reported receiving financial aids as an investigator, consultant, and speaker from AbbVie, BMS, Eli Lilly, and various other drug companies. All other authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


Medscape
19 minutes ago
- Medscape
Brain-Boosting Supplements: All Hype or Some Hope?
Media consumers are bombarded daily with aggressive, testimonial-driven ads for pricey supplements purported to sharpen memory, focus, and working brain function. Some even claim to stop or slow the development of dementia. Patients, especially older adults, may express interest in these supplements during clinic visits. Most claim to be 'clinically tested.' However, since the FDA exercises only limited regulatory control over these products, they are not held to the same purity, safety, and efficacy standards as are FDA-approved drugs. 'Manufacturers have a lot of leeway to market them as they want,' said Pieter Cohen, MD, director of the Supplement Research Program at the Cambridge Health Alliance in Somerville, Massachusetts, and an associate professor of medicine at Harvard Medical School in Boston. 'That's not to say they haven't been studied — there might be small studies posted online done in, say, 100 people in another country, for example.' Pieter Cohen, MD Cohen, therefore, does not generally recommend that his patients take them to improve brain health, 'although I do recommend supplements to patients who need them to treat medical conditions,' he told Medscape Medical News . Many contain dubious or unlisted ingredients, he noted. In a 2021 study of over-the-counter (OTC) cognitive enhancement supplements, Cohen and colleagues identified unapproved drugs (omberacetam, aniracetam, phenibut, vinpocetine, and picamilon) — as well as compounds not listed on the label and with unknown health effects. For those products with ingredient quantities provided on the labels, 75% of declared quantities were inaccurate. These OTC brain enhancers may feature, alone or in combination, nonpharmaceutical ingredients such as vitamins (including vitamin E), minerals like magnesium, omega-3 fatty acids, turmeric, and herbal compounds like ginseng, Ginkgo biloba , and coffee fruit extract. Some feature alleged boosters of brain performance that are less familiar, including alpha-GPC (L-alpha-glycerylphosphorylcholine), huperzine A, the Chinese mushroom lion's mane, L-carnitine, and the Ayurvedic medicine compound Bacopa monnieri . Some ingredients are more exotic. The memory enhancer Prevagen, for example, contains apoaequorin, a lab-made version of a protein found in the bioluminescent jellyfish Aequorea victoria . In 2024, the Federal Trade Commission and a federal district court in New York State ordered Prevagen's makers to stop their claims on the grounds they lacked reliable evidence. Jayne Zhang, MD The brain health supplements all have one thing in common, noted Jayne Zhang, MD, an attending neurologist specializing in cerebrovascular disease at Johns Hopkins School of Medicine in Baltimore — uncertain evidence of claimed efficacy. 'There is some modest support for a benefit from these products in people who already have nutritional deficiencies or mental degeneration, but there's not a lot of strong evidence from rigorous trials,' she told Medscape Medical News . Added Alejandra Sánchez López, MD, an assistant clinical professor of neurology and geriatric medicine at the Mary S. Easton Center for Alzheimer's Disease Research at the University of California, Los Angeles, 'Weak evidence of benefit usually comes from studies with small sample sizes and sponsored by the manufacturing company.' Alejandra Sánchez López, MD Like Cohen, Sánchez López recommends that her patients not take the brain supplements. 'They come with palpable GI [gastrointestinal] side effects such as nausea and diarrhea,' she said. Zhang is more open to patients' hopeful inquiries. 'I try not to be dismissive. Instead, I ask them what they're hoping a supplement will do for them, then I reveal what we know about them and talk about safety.' Zhang uses these encounters with OTC nootropics to talk about improving cognitive function in other ways: good nutrition, exercise, sleep, alcohol reduction, and social engagement, as well as proven medical therapies that mitigate cognition-impairing conditions such as depression, hyperglycemia, and hypertension. 'Patients need to understand there is no magic pill for brain health,' she said. The old-fashioned multivitamin tablet shows some promise, however. In a large National Institutes of Health-funded, placebo- and comparator-controlled randomized trial, Baker and colleagues found that older adults given a multivitamin had higher global cognition scores than those who did not take it. Specific effects on global cognition, episodic memory, and executive function were noted. The improvement was most pronounced in those with a history of cardiovascular disease. Safety Potential toxicity must be an issue with any loosely or unregulated OTC supplement, especially if taken over the long term. A content analysis of 12 cognitive supplements found the majority had at least one ingredient listed but not detected or, conversely, contained compounds detected but not reported on the label. And as noted, they can contain unapproved and potentially dangerous drugs. Drug interactions are another safety issue. Some dietary supplements can affect the pharmacokinetics of prescription drugs, altering their absorption, metabolism, or excretion and decreasing or increasing their potency. So, clinicians need to urge patients to be cautious, Sánchez López said. 'I always ask my patients to show me what supplements they're taking, and I go over the ingredient list.' A Dietetic Approach to Cognitive Health Emma Laing, PhD, RDN, a clinical professor and director of dietetics at the University of Georgia in Athens, Georgia, noted that a safer, proven alternative to commercial cognitive supplements can be found in the kitchen. 'While genetic predisposition, medical conditions, and environment are strongly linked to brain health, consuming a wide variety of nutrient-dense foods can improve cognitive health and reduce your risk for chronic disease,' she told Medscape Medical News . Emma Laing, PhD, RDN Minimally processed, nutrient-dense foods have been shown to support neurologic health, along with coffee and tea, Laing added. And even a small reduction in alcohol intake can improve cognitive function. Both the Mediterranean diet and the 'brain-healthy' MIND Diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) — a hybrid of the Mediterranean and DASH (Dietary Approaches to Stop Hypertension) regimens — have been well studied for their potential role in supporting cognitive function, memory, and alertness. Nootropics with cognitive potential are under ongoing evaluation, but until large scientific studies establish a positive effect of commercial brain health supplements on cognition, a healthy lifestyle may deliver more solid benefits to the brain.